Preference of elderly patients' to oral or intravenous chemotherapy in heavily pre-treated recurrent ovarian cancer: final results of a prospective multicenter trial.

ABSTRACT:

Background

Palliative systemic treatment in elderly gynaecological cancer patients remains a major challenge. In recurrent ovarian cancer (ROC), treosulfan an active alkylating drug showed similar cytotoxicity whether as oral (p.o.) or intravenous (i.v.) application. The aim of this innovative trial was to evaluate the preference of elderly patients (≥65 years) for p.o. or i.v. chemotherapy focusing compliance, outcome, toxicities, and geriatric aspects as secondary endpoints.

Methods

Patients with ROC had the free choice between treosulfan i.v. (7000 mg/m² d1, q29d) or p.o. (600 mg/m² daily d1-28, q57d). Only indecisive participants were randomized.

Results

Overall 123 patients with 2^nd to 5^th recurrence were registered and

SUBMITTER: Chekerov R 

PROVIDER: S-EPMC5341434 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature